Publication:
The influence of VKORC1 polymorphisms on warfarin doses in thai patients with deep vein thrombosis

dc.contributor.authorNuttawut Sermsathanasawadien_US
dc.contributor.authorChukij Sritongsathianen_US
dc.contributor.authorNunthapol Pongrattanamanen_US
dc.contributor.authorBanjerd Praditsuktavornen_US
dc.contributor.authorKiattisak Hongkuen_US
dc.contributor.authorChumpol Wongwaniten_US
dc.contributor.authorChanean Ruangsetakiten_US
dc.contributor.authorKhamin Chinsakchaien_US
dc.contributor.authorPramook Mutiranguraen_US
dc.contributor.authorNaravat Poungvarinen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-11-23T10:51:33Z
dc.date.available2018-11-23T10:51:33Z
dc.date.issued2015-01-01en_US
dc.description.abstract© 2015, Medical Association of Thailand. All rights reserved. Background: Polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase complex, subunit 1 genes (CYP2C9 and VKORC1, respectively) were previously shown to affect the warfarin dose required in anticoagulant therapy of deep vein thrombosis (DVT). However, little is known about the role of these genetic variants in the Thai population. Objective: To identify the effect of CYP2C9 and VKORC1 genetic variants on warfarin dosage in the Thai population with DVT. Material and Method: Genotyping of CYP2C9 (*2 and *3) and VKORC1 promoter (-1639G>A) variants were carried out in 97 Thai DVT patients receiving constant warfarin therapy and with a stable international normalized ratio using real-time PCR assays. Results: VKORC1 AA, GA, and GG genotype frequencies were found to be 49.5%, 46.4%, and 4.1%, respectively, while those of CYP2C9 genotypes were 88.7% for *1/*1 and 11.3% for *1/*3. The CYP2C9*2 variant was not present in the patients studied. The mean daily warfarin dose required to maintain a therapeutic INR differed significantly according to VKORC1 genotype, with 3.6 mg/day required for AA, 4.7 mg/day for GA, and 7.4 mg/day for GG (p-value <0.001). The CYP2C9 genotype did not significantly affect the warfarin dosage requirement (p-value = 0.29). Conclusion: These findings underline the impact of VKORC1 genotypes on the wide variation in warfarin maintenance dosing in Thai patients with DVT.en_US
dc.identifier.citationJournal of the Medical Association of Thailand. Vol.98, No.6 (2015), 549-554en_US
dc.identifier.issn01252208en_US
dc.identifier.issn01252208en_US
dc.identifier.other2-s2.0-84933518407en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/36540
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84933518407&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleThe influence of VKORC1 polymorphisms on warfarin doses in thai patients with deep vein thrombosisen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84933518407&origin=inwarden_US

Files

Collections